The Ledger

ABBV

Abbvie IncHealth Careinsider_universe

Last close $261.77Sep 13, 2026

Day +1.81%

Currently held

Agent 20 — SIR Price/Volumelong
7 sh @ $229.96 · stop $214.05
+$222.67 unrealized

Everything we've seen

·Sep 14, 3:20 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 3:20 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 3:05 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 3:05 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 2:50 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 2:50 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 2:35 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 2:35 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 2:20 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 2:20 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 2:20 PMstreamnews
Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA
A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put the right stocks inside it. Five blue chips with records stretching back decades make a compelling case for why account placement matters as much as stock selection.
·Sep 14, 2:20 PMstreamnews
AbbVie’s Latest Migraine Success Strengthens its Growth Story
AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles. The treatment […]
·Sep 14, 2:20 PMstreamnews
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
·Sep 14, 2:06 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 2:06 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 1:50 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 1:50 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 1:35 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 1:35 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 1:20 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 1:20 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 1:05 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 1:05 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 12:50 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 12:50 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 12:35 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 12:35 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 12:20 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 12:20 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 12:05 PMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 12:05 PMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 11:51 AMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 11:51 AMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
·Sep 14, 11:35 AMstreamnews
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
·Sep 14, 11:35 AMstreamnews
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
❖Sep 14, 11:00 AMnewsvia finnhub
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
❖Sep 14, 11:00 AMnewsvia finnhub
AbbVie’s Latest Migraine Success Strengthens its Growth Story
AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles. The treatment […]
❖Sep 14, 10:07 AMnewsvia finnhub
Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA
A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put the right stocks inside it. Five blue chips with records stretching back decades make a compelling case for why account placement matters as much as stock selection.
?Sep 14, 9:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.38% today with no headline catalyst identified, suggesting this is flow-driven — likely institutional buying or sector rotation into defensives/healthcare. The macro context is mildly supportive: a T10Y2Y at 1.9σ below trend (i.e., a relatively flat or slightly inverted curve) historically favors defensive sectors like large-cap pharma/biotech, which ABBV occupies. With 370 minutes remaining (effectively a full trading day still ahead, given this appears to be early-to-mid session), there is ample time for continuation. No reversal signal or fade pattern is noted. The absence of news does not disqualify momentum — 2.38% moves of this size reflect real conviction from size players. However, without a confirmed catalyst or volume confirmation data, and given the move has already captured meaningful ground (reducing asymmetry to the +3% target from current levels), I assign a moderate continuation probability. The setup warrants a position by the system's own asymmetric risk framework — bounded downside via -1.5% stop, meaningful upside to +3% target.
!Sep 14, 9:36 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is up 2.38% today with no headline catalyst identified, suggesting this is flow-driven — likely institutional buying or sector rotation into defensives/healthcare. The macro context is mildly supportive: a T10Y2Y at 1.9σ below trend (i.e., a relatively flat or slightly inverted curve) historically favors defensive sectors like large-cap pharma/biotech, which ABBV occupies. With 370 minutes remaining (effectively a full trading day still ahead, given this appears to be early-to-mid session), there is ample time for continuation. No reversal signal or fade pattern is noted. The absence of news does not disqualify momentum — 2.38% moves of this size reflect real conviction from size players. However, without a confirmed catalyst or volume confirmation data, and given the move has already captured meaningful ground (reducing asymmetry to the +3% target from current levels), I assign a moderate continuation probability. The setup warrants a position by the system's own asymmetric risk framework — bounded downside via -1.5% stop, meaningful upside to +3% target.
❖Sep 14, 7:52 AMnewsvia finnhub
How Much You Need Invested to Cover Your Medicare Premiums With Dividend Income
Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.
❖Sep 12, 6:53 PMnewsvia finnhub
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
❖Sep 12, 2:20 AMnewsvia finnhub
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
❖Sep 11, 3:11 PMnewsvia finnhub
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
❖Sep 11, 1:48 PMnewsvia finnhub
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
❖Sep 11, 11:26 AMnewsvia finnhub
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
❖Sep 11, 10:22 AMnewsvia finnhub
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
❖Sep 11, 8:02 AMnewsvia finnhub
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
There are currently no targeted therapies specifically approved for menstrual migraine, though other anti-migraine drugs are used off-label in this indication.
❖Sep 11, 7:47 AMnewsvia finnhub
How Much Dividend Income Can You Buy With $250,000?
A $250,000 rollover sounds like a clean starting point until you realize yield alone is not the whole story, and only one name on this roster actually clears the current Treasury rate. Here is what the math, the coverage ratios, and 43-year dividend streaks reveal about building real income from a common account balance.
❖Sep 11, 6:28 AMnewsvia finnhub
What's Going On With AbbVie Stock Friday?
AbbVie shares are edging higher Friday following Thursday's positive Phase 3 trial results for its menstrual migraine drug, atogepant.
❖Sep 10, 11:24 PMnewsvia finnhub
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
❖Sep 10, 3:10 PMnewsvia finnhub
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
❖Sep 10, 2:17 PMnewsvia finnhub
AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
❖Sep 10, 2:14 PMnewsvia finnhub
AbbVie Gains as Qulipta Opens a New Migraine Market
The Phase 3 victory supports intermittent treatment, potentially expanding use without requiring continuous daily dosing.
❖Sep 10, 1:57 PMnewsvia finnhub
JNJ Stock: Is the Rally Running Out of Steam?
A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.
❖Sep 10, 1:46 PMnewsvia finnhub
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
❖Sep 10, 1:05 PMnewsvia finnhub
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.
❖Sep 10, 11:54 AMnewsvia finnhub
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
❖Sep 10, 11:05 AMnewsvia finnhub
Why Has AbbVie Gone Quiet About Humira?
AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.
❖Sep 10, 8:55 AMnewsvia finnhub
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults.1 These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks.
❖Sep 10, 8:41 AMnewsvia finnhub
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
❖Sep 10, 6:10 AMnewsvia finnhub
HSBC Maintains Buy on AbbVie, Raises Price Target to $315
HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.
❖Sep 10, 5:21 AMnewsvia finnhub
Pfizer: Firing On All Cylinders
Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough. Read why PFE stock is a buy.
❖Sep 10, 4:58 AMnewsvia finnhub
AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo
These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent
❖Sep 9, 10:32 PMnewsvia finnhub
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
❖Sep 9, 7:05 PMnewsvia finnhub
Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J. Icotyde could appeal to patients who prefer a pill over an injectable treatment, potentially […]
❖Sep 9, 4:58 PMnewsvia finnhub
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]
❖Sep 9, 4:41 PMnewsvia finnhub
What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
❖Sep 9, 2:45 PMnewsvia finnhub
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.76%. Currently, AbbVie has a market capitalization of $445.73 billion.
❖Sep 9, 12:05 PMnewsvia finnhub
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
❖Sep 9, 11:46 AMnewsvia finnhub
VERAXA Biotech Designates Raju Willener as CFO
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.
❖Sep 9, 9:47 AMnewsvia finnhub
AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 10:15 AM EDTCompany ParticipantsScott Reents - Executive VP &...
❖Sep 9, 8:00 AMnewsvia finnhub
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
❖Sep 9, 6:54 AMnewsvia finnhub
AbbVie Exec Says Balance Sheet And Growth Runway Allow Company To Consider Both Early- And Late-Stage Business Development Opportunities
- conference call
❖Sep 9, 6:20 AMnewsvia finnhub
Billionaire Israel Englander Is Doubling Down on These 2 Outstanding Dividend Stocks. Should You?
Dividend seekers can hardly go wrong with these companies.
❖Sep 8, 5:45 PMnewsvia finnhub
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.
❖Sep 8, 1:08 PMnewsvia finnhub
Is AbbVie Stock Too Reliant On Skyrizi?
AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.
❖Sep 8, 1:05 PMnewsvia finnhub
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.
❖Sep 8, 10:36 AMnewsvia finnhub
What Merck Stopped Saying About GARDASIL Should Change What You Watch
Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.
?Sep 8, 10:21 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 2.28% today with ~325 minutes remaining — substantial time for continuation but also room for intraday recovery. The headline is a market assessment report, not a catalyst for the move, so the selloff appears to be macro or flow-driven rather than news-specific. The macro context (5Y5Y inflation forward at 1.7σ above trend) suggests elevated rates environment, which is modestly negative for large-cap pharma/biotech multiples but not acutely so. A -2.28% move represents meaningful selling conviction, and without a clear reversal signal or counter-catalyst, the path of least resistance into the close is modestly lower. However, no strong continuation pressure is identifiable — no confirmed volume spike, no negative news driver, and the move may have already absorbed the bulk of the selling. Probability set conservatively above 0.5 given the size of the move and time remaining, but confidence is low — this is a borderline momentum read.
!Sep 8, 10:21 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 2.28% today with ~325 minutes remaining — substantial time for continuation but also room for intraday recovery. The headline is a market assessment report, not a catalyst for the move, so the selloff appears to be macro or flow-driven rather than news-specific. The macro context (5Y5Y inflation forward at 1.7σ above trend) suggests elevated rates environment, which is modestly negative for large-cap pharma/biotech multiples but not acutely so. A -2.28% move represents meaningful selling conviction, and without a clear reversal signal or counter-catalyst, the path of least resistance into the close is modestly lower. However, no strong continuation pressure is identifiable — no confirmed volume spike, no negative news driver, and the move may have already absorbed the bulk of the selling. Probability set conservatively above 0.5 given the size of the move and time remaining, but confidence is low — this is a borderline momentum read.
❖Sep 8, 7:27 AMnewsvia finnhub
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
❖Sep 8, 4:08 AMnewsvia finnhub
Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca
Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid
❖Sep 6, 8:50 AMnewsvia finnhub
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
❖Sep 5, 9:30 AMnewsvia finnhub
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
❖Sep 5, 5:04 AMnewsvia finnhub
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Owning these dividend stocks could be a simple way to make money over the long term.
❖Sep 4, 7:14 PMnewsvia finnhub
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
❖Sep 4, 2:50 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
❖Sep 4, 12:57 PMnewsvia finnhub
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
?Sep 1, 9:37 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 1.64% today, a moderate but meaningful move. The sole relevant headline flags potential Trump admin drug pricing curbs targeting biotechs, which is a headwind for the sector and could cap or fade ABBV's gain — though ABBV is technically pharma/immunology rather than pure biotech, the sentiment overhang is real. Macro context shows elevated 2Y yields (2σ above trend), which is generally a mild negative for long-duration assets including healthcare equities with rich valuations. However, the move itself reflects genuine buying conviction and at 1.64% is not yet at a magnitude that screams exhaustion or crowded long. With 369 minutes remaining (well over 6 hours, though the market closes at 4 PM so this implies we are early in the session), there is ample time for the move to extend. The policy headline is a modest drag but not a confirmed catalyst for reversal — no specific ABBV-targeting news. On balance, momentum favors slight continuation with no strong reason to fade, but the regulatory overhang and elevated rate environment prevent a high-confidence read. Probability set modestly above the 0.5 threshold.
!Sep 1, 9:37 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is up 1.64% today, a moderate but meaningful move. The sole relevant headline flags potential Trump admin drug pricing curbs targeting biotechs, which is a headwind for the sector and could cap or fade ABBV's gain — though ABBV is technically pharma/immunology rather than pure biotech, the sentiment overhang is real. Macro context shows elevated 2Y yields (2σ above trend), which is generally a mild negative for long-duration assets including healthcare equities with rich valuations. However, the move itself reflects genuine buying conviction and at 1.64% is not yet at a magnitude that screams exhaustion or crowded long. With 369 minutes remaining (well over 6 hours, though the market closes at 4 PM so this implies we are early in the session), there is ample time for the move to extend. The policy headline is a modest drag but not a confirmed catalyst for reversal — no specific ABBV-targeting news. On balance, momentum favors slight continuation with no strong reason to fade, but the regulatory overhang and elevated rate environment prevent a high-confidence read. Probability set modestly above the 0.5 threshold.
?Aug 28, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 1.81% today, which is a meaningful move but sits just below the 2% threshold that would signal stronger conviction. With 355 minutes remaining (nearly a full trading day's worth of remaining session time), there is ample runway for continuation if selling pressure persists. However, several factors temper enthusiasm for a strong continuation call: (1) No news catalyst is identified, meaning the move may be technical or flow-driven rather than fundamentally anchored, which increases fade risk as the session progresses; (2) The macro context (elevated mortgage rates) is not directly relevant to ABBV as a large-cap pharma/biotech name — no sector tailwind or headwind from FRED data applies here; (3) The move is real but not outsized enough to indicate panic or forced selling. On balance, the momentum is modestly negative and the default lean per framework guidelines is to favor continuation absent a clear reversal signal. Probability set just above the 0.5 threshold — borderline continuation with no strong reason to fade.
!Aug 28, 9:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 1.81% today, which is a meaningful move but sits just below the 2% threshold that would signal stronger conviction. With 355 minutes remaining (nearly a full trading day's worth of remaining session time), there is ample runway for continuation if selling pressure persists. However, several factors temper enthusiasm for a strong continuation call: (1) No news catalyst is identified, meaning the move may be technical or flow-driven rather than fundamentally anchored, which increases fade risk as the session progresses; (2) The macro context (elevated mortgage rates) is not directly relevant to ABBV as a large-cap pharma/biotech name — no sector tailwind or headwind from FRED data applies here; (3) The move is real but not outsized enough to indicate panic or forced selling. On balance, the momentum is modestly negative and the default lean per framework guidelines is to favor continuation absent a clear reversal signal. Probability set just above the 0.5 threshold — borderline continuation with no strong reason to fade.
?Aug 27, 2:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 1.71% today, which is a moderate but not extreme intraday move. There are no recent headlines to explain the move, which makes it harder to assess conviction behind the selling. The macro context (elevated mortgage rates at 1.8σ above trend) is not directly relevant to ABBV as a large-cap pharma/biotech name — it does not meaningfully pressure or support the stock. With 100 minutes remaining, there is ample time for continuation if momentum is real, but the move sits just below the 2% threshold that would signal stronger conviction. Without a clear catalyst, this looks like it could be idiosyncratic flow or broad market drift rather than a sustained directional thesis. The absence of news cuts both ways — no catalyst to sustain the downside, but also no reversal trigger. Balancing the moderate move magnitude against the lack of supporting narrative and no sector tailwind for the selloff, this edges just below the 0.5 threshold. The risk/reward of a short here is not clearly favorable enough to trigger a position.
!Aug 27, 2:05 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 1.71% today, which is a moderate but not extreme intraday move. There are no recent headlines to explain the move, which makes it harder to assess conviction behind the selling. The macro context (elevated mortgage rates at 1.8σ above trend) is not directly relevant to ABBV as a large-cap pharma/biotech name — it does not meaningfully pressure or support the stock. With 100 minutes remaining, there is ample time for continuation if momentum is real, but the move sits just below the 2% threshold that would signal stronger conviction. Without a clear catalyst, this looks like it could be idiosyncratic flow or broad market drift rather than a sustained directional thesis. The absence of news cuts both ways — no catalyst to sustain the downside, but also no reversal trigger. Balancing the moderate move magnitude against the lack of supporting narrative and no sector tailwind for the selloff, this edges just below the 0.5 threshold. The risk/reward of a short here is not clearly favorable enough to trigger a position.
?Aug 27, 11:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 1.57% today, which is a modest but real move. However, several factors temper continuation confidence. First, the macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend at 2.33 — elevated inflation expectations can pressure rate-sensitive and high-multiple sectors, but ABBV as a large-cap pharma/biotech is not a primary rate-sensitive name, so this macro signal is only weakly applicable. Second, there are no news catalysts to sustain selling pressure — absence of headlines means the move may be technical or sympathy-driven, which tends to fade rather than accelerate. Third, at 230 minutes remaining there is ample time for a reversal, but also enough time for continuation if flow persists. Fourth, 1.57% is below the 2% threshold where momentum typically self-sustains with high confidence. The move is real but modest, no catalyst to drive further selling, and macro context is only tangentially bearish for this name. The setup is borderline — not enough to confidently call continuation, and the lack of a news driver mildly favors mean reversion into the close. Probability falls just below the 0.5 trigger threshold.
!Aug 27, 11:56 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 1.57% today, which is a modest but real move. However, several factors temper continuation confidence. First, the macro context shows 5-year forward inflation expectations (T5YIFR) running 1.6σ above trend at 2.33 — elevated inflation expectations can pressure rate-sensitive and high-multiple sectors, but ABBV as a large-cap pharma/biotech is not a primary rate-sensitive name, so this macro signal is only weakly applicable. Second, there are no news catalysts to sustain selling pressure — absence of headlines means the move may be technical or sympathy-driven, which tends to fade rather than accelerate. Third, at 230 minutes remaining there is ample time for a reversal, but also enough time for continuation if flow persists. Fourth, 1.57% is below the 2% threshold where momentum typically self-sustains with high confidence. The move is real but modest, no catalyst to drive further selling, and macro context is only tangentially bearish for this name. The setup is borderline — not enough to confidently call continuation, and the lack of a news driver mildly favors mean reversion into the close. Probability falls just below the 0.5 trigger threshold.
?Aug 27, 10:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down ~2% today with no identifiable headline catalyst, suggesting this is flow/technical driven. The macro context shows elevated 5Y5Y forward inflation expectations (1.6σ above trend), which creates a modestly risk-off environment that can weigh on large-cap healthcare names. With 334 minutes remaining (roughly 5.5 hours — this appears to be early-to-mid session), there is ample time for the move to extend. However, a ~2% drop in a defensive healthcare name like ABBV without news often attracts dip buyers, particularly in the afternoon session. The absence of news cuts both ways: no panic catalyst but also no clear reason to reverse aggressively. The elevated inflation expectations environment is mildly rate-sensitive and could sustain mild selling pressure. Overall, the balance of evidence marginally favors continuation of the downside given sustained session pressure and macro headwinds, but conviction is low — this is a borderline read leaning down.
!Aug 27, 10:11 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down ~2% today with no identifiable headline catalyst, suggesting this is flow/technical driven. The macro context shows elevated 5Y5Y forward inflation expectations (1.6σ above trend), which creates a modestly risk-off environment that can weigh on large-cap healthcare names. With 334 minutes remaining (roughly 5.5 hours — this appears to be early-to-mid session), there is ample time for the move to extend. However, a ~2% drop in a defensive healthcare name like ABBV without news often attracts dip buyers, particularly in the afternoon session. The absence of news cuts both ways: no panic catalyst but also no clear reason to reverse aggressively. The elevated inflation expectations environment is mildly rate-sensitive and could sustain mild selling pressure. Overall, the balance of evidence marginally favors continuation of the downside given sustained session pressure and macro headwinds, but conviction is low — this is a borderline read leaning down.
?Aug 26, 2:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
!Aug 26, 2:05 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
?Aug 26, 12:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 1.51% today, which is a moderate but not outsized move. The headline present is about TG Therapeutics/Briumvi and is not directly relevant to ABBV — no clear catalyst driving the move. With 189 minutes remaining there is ample time for continuation, but the macro context is a mild headwind: elevated 5Y5Y inflation forward rates (1.6σ above trend) suggest rate-sensitive pressure broadly, though ABBV as a large-cap pharma/biotech is not the most rate-sensitive sector. The move itself (-1.51%) is real flow but sits at the lower boundary of 'meaningful conviction' range. Without a clear news catalyst and given that elevated inflation expectations can support defensive rotation back into large-cap pharma (a potential reversal driver), the balance of evidence is slightly against continuation. The absence of a strong directional catalyst and lack of sector-specific negative news tips this just below the 0.5 threshold.
!Aug 26, 12:36 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 1.51% today, which is a moderate but not outsized move. The headline present is about TG Therapeutics/Briumvi and is not directly relevant to ABBV — no clear catalyst driving the move. With 189 minutes remaining there is ample time for continuation, but the macro context is a mild headwind: elevated 5Y5Y inflation forward rates (1.6σ above trend) suggest rate-sensitive pressure broadly, though ABBV as a large-cap pharma/biotech is not the most rate-sensitive sector. The move itself (-1.51%) is real flow but sits at the lower boundary of 'meaningful conviction' range. Without a clear news catalyst and given that elevated inflation expectations can support defensive rotation back into large-cap pharma (a potential reversal driver), the balance of evidence is slightly against continuation. The absence of a strong directional catalyst and lack of sector-specific negative news tips this just below the 0.5 threshold.
?Aug 26, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 1.60% mid-session, a meaningful but not exceptional move. There is no direct ABBV-specific headline driving the decline today — the only nearby headline concerns a competitor (TG Therapeutics/Briumvi upgrade), which could modestly weigh on ABBV's MS franchise but is a soft, indirect pressure at best. The macro context shows 5Y5Y inflation forward running 1.6σ above trend, which is a mild headwind for rate-sensitive and high-multiple biotech/pharma names, consistent with a defensive rotation out of higher-valuation healthcare names. With 360 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend. No clear reversal signal is present — the move is orderly and not spiking back. However, ABBV is a large-cap, lower-beta pharma name that tends to mean-revert without a hard catalyst; the lack of a direct negative headline limits conviction in continuation. On balance, modest continuation probability slightly above the threshold — the macro backdrop and competitor news provide a plausible narrative for sellers to remain in control into the close, but this is a low-conviction setup.
!Aug 26, 9:46 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ABBV is down 1.60% mid-session, a meaningful but not exceptional move. There is no direct ABBV-specific headline driving the decline today — the only nearby headline concerns a competitor (TG Therapeutics/Briumvi upgrade), which could modestly weigh on ABBV's MS franchise but is a soft, indirect pressure at best. The macro context shows 5Y5Y inflation forward running 1.6σ above trend, which is a mild headwind for rate-sensitive and high-multiple biotech/pharma names, consistent with a defensive rotation out of higher-valuation healthcare names. With 360 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend. No clear reversal signal is present — the move is orderly and not spiking back. However, ABBV is a large-cap, lower-beta pharma name that tends to mean-revert without a hard catalyst; the lack of a direct negative headline limits conviction in continuation. On balance, modest continuation probability slightly above the threshold — the macro backdrop and competitor news provide a plausible narrative for sellers to remain in control into the close, but this is a low-conviction setup.
✓Jul 31, 10:50 AMdecisionacted
Agent 7 — Day Trader — decide: buy
ABBV is down ~1.9% on earnings-driven selling: the company beat on revenue but cut profit guidance due to the Apogee acquisition cost drag. Multiple headlines confirm the market's negative reaction is guidance-driven, not a temporary misread — that type of downward guidance revision tends to attract sustained selling as analysts and institutional investors reprice. There is no macro tailwind for pharma today (macro context is mortgage-rate focused, sector-neutral for ABBV). With ~295 minutes remaining there is ample time for continuation. The move is meaningful but not extreme, suggesting it hasn't fully exhausted sellers. No reversal signal is visible — the stock appears to be in a steady decline rather than a sharp gap-and-fade. The main counterweight is that some of the bad news (guidance cut) may already be partially digested given the stock is off but not dramatically so, and the revenue beat provides a partial floor. On balance, modest continuation downward into the close is the higher-probability outcome.
▢Jul 30, 8:00 PMjournal
Agent 7 — Day Trader opened short 11 @ $252.53
▣Jul 30, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed short 11 @ $252.68 (-$1.60)
EOD forced close — day trader never carries overnight
?Jul 9, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
Only 10 minutes remain until the forced 3:45 PM ET close, which severely limits any further directional move. The -1.55% decline is modest and below the 2-5% threshold that would signal strong institutional conviction. No ABBV-specific negative catalyst is present in the headlines — the CF market article is neutral/background, and the AMGN headline is unrelated. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening) mildly favors defensives like ABBV, which could support a slight bid into the close rather than continued selling. With the position already down ~$3.93 from prior close and end-of-day window-dressing or short-covering common in the final minutes, the risk of a fade/reversal is meaningful. Time constraint alone drives the probability well below 0.5 — there is simply insufficient runway for the move to extend materially even if the thesis were correct.
!Jul 9, 3:35 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
Only 10 minutes remain until the forced 3:45 PM ET close, which severely limits any further directional move. The -1.55% decline is modest and below the 2-5% threshold that would signal strong institutional conviction. No ABBV-specific negative catalyst is present in the headlines — the CF market article is neutral/background, and the AMGN headline is unrelated. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening) mildly favors defensives like ABBV, which could support a slight bid into the close rather than continued selling. With the position already down ~$3.93 from prior close and end-of-day window-dressing or short-covering common in the final minutes, the risk of a fade/reversal is meaningful. Time constraint alone drives the probability well below 0.5 — there is simply insufficient runway for the move to extend materially even if the thesis were correct.
!Jul 2, 6:03 PMsignal
options_momentum — insufficient_capital
!Jul 2, 5:45 PMsignal
options_momentum — insufficient_capital
!Jul 2, 5:31 PMsignal
options_momentum — insufficient_capital
!Jul 2, 5:16 PMsignal
options_momentum — insufficient_capital
!Jul 2, 5:04 PMsignal
options_momentum — insufficient_capital
!Jul 2, 4:46 PMsignal
options_momentum — insufficient_capital
!Jul 2, 4:33 PMsignal
options_momentum — insufficient_capital
!Jul 2, 4:16 PMsignal
options_momentum — insufficient_capital
!Jul 2, 4:05 PMsignal
options_momentum — insufficient_capital
!Jul 2, 3:46 PMsignal
options_momentum — insufficient_capital
!Jul 2, 3:33 PMsignal
options_momentum — insufficient_capital
!Jul 2, 3:17 PMsignal
options_momentum — insufficient_capital
!Jul 2, 2:46 PMsignal
options_momentum — insufficient_capital
!Jul 2, 2:33 PMsignal
options_momentum — insufficient_capital
!Jul 2, 2:18 PMsignal
options_momentum — insufficient_capital
!Jul 2, 2:07 PMsignal
options_momentum — insufficient_capital
!Jul 2, 1:47 PMsignal
options_momentum — insufficient_capital
!Jul 2, 1:35 PMsignal
options_momentum — insufficient_capital
!Jul 2, 1:18 PMsignal
options_momentum — insufficient_capital
✓Jun 22, 6:06 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] From 2026-06-08 through 2026-06-18, ABBV carved out a tight consolidation cluster between $216.49 and $227.73 on subdued, declining volume (ranging 4.1M–5.9M, well beneath the 20-day ADV of 5.5M), with the last session of that cluster (2026-06-18, close $216.49, volume 9.6M) a high-volume down-day that appeared to flush weak holders. Today's bar (2026-06-22) then broke decisively above the entire cluster with a +6.22% gain to $229.96 on 13.1M shares — a volume z-score of +5.74 — representing roughly 2.4× the trailing ADV and the single heaviest volume day in the 20-day window by a wide margin. Under the SIR 2-D framework, this trajectory — a path that compresses horizontally (volume contracting while price idles), followed by a sharp up-and-right leap — is the textbook cluster_break_up signal, suggesting fresh demand decisively absorbed the available float at higher prices. Risks: The signal rests on a single extraordinary bar (2026-06-22), and SIR methodology cautions that one-bar breakouts without subsequent confirming sessions carry elevated failure risk — a close back below the cluster midpoint (~$222–$224) on expanding volume in the next 1–3 sessions would strongly indicate a false break and invalidate the read. Additionally, the macro context (5-year inflation expectations 1.5σ below trend as of 2026-06-18) could weigh on risk appetite broadly, and if today's catalyst (likely a binary event such as clinical data or guidance) proves transient or is revised, the volume spike could recast as exhaustion rather than accumulation.
?Jun 22, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 4.68% today, a meaningful move indicating real institutional flow and conviction. With 330 minutes remaining (well into the session but still substantial time before the 3:45 PM cutoff), there is room for continuation. No news catalyst is identified, which is not unusual — large pharmaceutical names frequently move on options activity, analyst upgrades, or pipeline-related flow that doesn't immediately surface in headlines. The macro context (5Y inflation breakevens 1.5σ below trend) is modestly relevant for healthcare/pharma in that a lower inflation expectations environment is generally supportive of defensive/dividend-paying sectors like large-cap pharma, which ABBV represents. No reversal pattern is described — the move appears directional rather than a morning gap fade. The absence of a clear catalyst and the already-extended 4.68% move introduce some fade risk as profit-takers may emerge, but the bounded risk profile of the setup (tight stop, fixed target, forced flatten) favors taking the trade at modest probability. Assigning 0.54 — slight lean toward continuation without strong confirmation signals.
?Jun 8, 1:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 2.55% intraday with no headline catalyst visible, suggesting either broad sector rotation or institutional distribution rather than a news-driven spike that might reverse quickly. The macro context shows a compressed yield curve (T10Y2Y at 2.5σ below trend), which is modestly supportive of defensives like pharma/biotech in a bear-flattening environment — this creates a slight headwind against further downside continuation, as defensive names can attract dip buyers when rates are flattening. However, a 2.55% move represents meaningful selling flow and without a reversal signal or clear exhaustion pattern noted, momentum modestly favors continuation. With 135 minutes remaining there is ample time for the move to extend. No reversal catalyst is present. The yield curve context provides a mild dampening effect on conviction, keeping this at low-probability continuation rather than a strong setup. Assigning modest continuation probability just above the threshold given the defensive sector tailwind partially offsetting the momentum signal.
?Jun 5, 2:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 1.88% on the day — a meaningful move showing real buying conviction, though not quite into the 2-5% range that would signal a more aggressive trend day. No news catalyst is identifiable, suggesting this is either sector rotation or institutional accumulation rather than a headline-driven spike prone to quick reversal. The macro context (T10Y2Y at 0.42, 1.9σ below trend) is modestly supportive for defensives like ABBV — a flattening/slightly inverted curve environment historically favors large-cap healthcare/defensive names as money rotates away from financials and cyclicals. With 89 minutes remaining there is ample time for continuation before the 3:45 PM cutoff. The main drag on conviction is the absence of any identifiable catalyst and no volume data to confirm institutional follow-through. The move is real but not exceptional, so I assign a modest continuation probability above the 0.5 threshold — enough to warrant a position given bounded risk parameters, but not a high-conviction setup.
?Jun 2, 9:31 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is down 2.20% with 375 minutes remaining (roughly 6+ hours of trading time, indicating this is early-to-mid session). The move is meaningful and suggests real institutional selling pressure. No headlines are available to explain the move, but absence of news does not disqualify momentum — large moves without obvious catalysts often reflect pre-positioned institutional flow or sector rotation rather than retail reaction to news. The macro context shows T10Y2Y at 0.42, notably 2.0σ below its 24-month trend, which is a mild bear-flattening signal that favors defensives like ABBV in theory — however, this is a double-edged dynamic: defensives can also see profit-taking when yield curves compress as investors rotate. With ample time remaining, if selling flow is sustained, there is room for further downside toward the +3% profit target from current levels (~$206.55). No reversal pattern is evident from the data provided. Balancing the modest move magnitude (2.2% — real but not extreme), no supportive newsflow, mild macro tailwind that is ambiguous for ABBV specifically, and meaningful time remaining, continuation probability is assessed at 0.52 — a modest lean toward continuation of the down move without strong conviction.
?May 22, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.28% intraday with no attributable headline, suggesting real institutional flow rather than a news pop that could fade on profit-taking. With 315 minutes remaining (roughly 5+ hours, implying this is early-to-mid session), there is meaningful time for the move to extend toward the close. No reversal signals are present in the data provided. The macro context (T10Y3M at +2.2σ above trend) is somewhat cautionary for risk assets broadly, but ABBV is a defensive large-cap pharma/biotech name that is not directly in the Banks or Recession-sensitive sectors flagged by the yield curve signal — so macro headwind is modest. Absence of news is not a disqualifier per the trading framework. The move is in the lower half of the 2-5% meaningful-flow range, suggesting conviction is present but not overwhelming. Overall, momentum favors modest continuation with no strong fade catalyst, warranting a slight lean toward upside continuation.
?May 19, 2:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.23% with 95 minutes remaining, representing meaningful intraday conviction and real flow. No news headlines are present, but absence of news is not disqualifying — this move reflects actual positioning. The macro context flags elevated 10Y breakeven inflation (2.48, 2.4σ above trend), which is a mild headwind for long-duration sensitive sectors; however, ABBV as a large-cap pharma/dividend name has moderate but not extreme duration sensitivity. The move magnitude (2.23%) is at the lower end of the 'meaningful' threshold, suggesting some but not overwhelming conviction. With 95 minutes remaining there is adequate time for continuation but also time for a partial fade. No reversal signals are evident from the data provided. On balance, momentum leans modestly toward continuation into the close, though the elevated inflation expectations environment introduces some drag. Assigning a modest continuation probability above 0.5 given the directional move and sufficient remaining session time, tempered by macro headwinds.
?May 19, 12:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.62% intraday with no attributable headline, suggesting the move is flow/positioning-driven rather than news-catalyzed. That cuts both ways — no catalyst to fade, but also no fundamental anchor to sustain it. With 190 minutes remaining there is meaningful time for continuation, but the macro context is a mild headwind: 10Y inflation breakevens running 2.4σ above trend typically pressures long-duration sensitive sectors, and large-cap pharma/biotech like ABBV carries some duration sensitivity given its dividend yield and defensive characteristics. No reversal pattern is evident from the data provided, and the move size (2.62%) is real but not extreme. Overall, this is a modest momentum setup with no strong reason to fade — probability sits just above neutral.
?May 19, 10:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.03% with ~305 minutes remaining, suggesting meaningful institutional flow with ample time for continuation. No headlines available to explain the move, which is common for flow-driven intraday setups. The macro context shows elevated inflation expectations (T10YIE 2.4σ above trend), which is modestly unfavorable for long-duration equities but ABBV is a defensive healthcare/pharma name with relatively low duration sensitivity — its dividend yield and defensive characteristics may actually attract rotation in a risk-off or inflation-hedging environment. The absence of a clear catalyst cuts both ways: no news means no obvious fade trigger, but also no fundamental anchor sustaining the move. A 2% move represents real conviction, and with over 5 hours remaining, momentum has room to run. No reversal signal is evident. Setting probability modestly above baseline given the size of move, time remaining, and defensive sector profile partially insulating from macro headwinds.
✓May 14, 1:08 PMdecisionacted
Agent 7 — Day Trader — decide: buy
ABBV is up 1.12% today, a modest but real move suggesting some directional flow. No headlines are present to explain the move, which is common and not disqualifying. The macro context flags elevated 5-year inflation expectations (T5YIE at 2.5σ above trend), which is more relevant to Gold, Energy, and TIPS sectors — ABBV as a large-cap pharma/biotech name is largely insulated from this inflationary signal, neither helped nor hurt materially. With 157 minutes remaining, there is ample time for continuation if momentum holds. However, the move is only 1.12%, which is below the threshold where strong conviction is clearly evident. No sector tailwind, no news catalyst, and no reversal signal visible — this is a borderline read. The asymmetric risk structure (tight -1.5% stop, +3% target, forced flatten) favors taking the trade at the margin. Assigning a slight lean toward continuation given time remaining and no contrary evidence.
▢May 13, 8:00 PMjournal
Agent 7 — Day Trader opened long 9 @ $210.83
▣May 13, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 9 @ $210.94 (+$0.94)
EOD forced close — day trader never carries overnight
?May 13, 9:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.51% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a thin-volume intraday spike. The macro context highlights elevated inflation expectations (T5YIE at 2.5σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 375 minutes remaining there is ample time for reversion, but without a clear catalyst, mean-reversion risk is roughly equal to continuation probability.
?May 13, 9:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.51% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated 5-year inflation expectations (2.69, 2.5σ above trend), which primarily benefits Gold, Energy, and TIPS sectors — not pharma/biotech — providing no tailwind for ABBV continuation. With 390 minutes remaining (a full trading day essentially), there is time for mean reversion, and without a clear fundamental catalyst, the gap-and-hold thesis is weak.
?May 13, 9:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.51% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this reflects genuine fundamental buying or a thin-volume gap. The macro context (elevated 5-year inflation breakevens at 2.5σ above trend) is not a typical tailwind for large-cap pharma like ABBV, which tends to be more rate-sensitive than inflation-sensitive. With 405 minutes remaining and no clear catalyst, mean-reversion risk is meaningful and the setup does not meet the threshold for a high-confidence continuation.
?May 12, 3:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.60% today with no identifiable catalyst from recent headlines, suggesting this may be a gap-up or broad market lift rather than a news-driven continuation setup. The macro context (elevated inflation expectations) is not particularly bullish for large-cap pharma like ABBV. With only 30 minutes remaining until the forced close cutoff, there is limited time for meaningful additional price discovery, and late-session mean reversion is a real risk on an unexplained move of this magnitude.
?May 12, 3:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.73% with no accompanying news headlines to explain the move, making it difficult to attribute the gain to a clear fundamental catalyst that would drive further continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma/biotech name like ABBV. With only 45 minutes remaining until the forced close, there is limited time for meaningful additional upside even if the move were catalyst-driven, and without a clear story the risk of mean reversion or profit-taking into the close is elevated.
?May 12, 2:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.84% with no identifiable news catalyst in the headlines, suggesting the move may be driven by sector rotation, options activity, or thin volume rather than a fundamental event. The macro context (elevated 5Y inflation expectations) is not directly supportive of a healthcare/pharma name like ABBV. With only 60 minutes remaining until the forced close, there is limited time for meaningful continuation, and without a clear catalyst, mean reversion or consolidation is equally plausible.
?May 12, 2:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.16% today with no identifiable headline catalyst in the last 24 hours, making it difficult to assess whether this move has fundamental support or is driven by technical flows or sector rotation. The macro context flags elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a clear tailwind for healthcare/pharma names like ABBV. With 74 minutes remaining, there is insufficient catalyst clarity to confidently expect continuation, and large gap-up moves without news often see partial mean reversion into the close.
?May 12, 2:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up ~2.87% with no identifiable news catalyst in the last 24 hours, suggesting the move may be gap-driven or sector-rotation-related rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not directly relevant to a large-cap pharma name like ABBV. With 90 minutes remaining and no clear continuation catalyst, mean reversion or consolidation near current levels is equally plausible as further upside.
?May 12, 2:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 3.19% with no identifiable news catalyst or earnings event driving the move, making it difficult to assess whether this is a sustainable directional trend or a gap/spike that may fade. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a healthcare/pharma name. With 105 minutes remaining and no clear fundamental catalyst, mean-reversion pressure after a ~3% intraday move is a real risk, and the lack of headlines leaves the driver ambiguous.
?May 12, 1:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has made a strong 3.62% move with 135 minutes remaining, but there are no identifiable catalysts in recent headlines to explain or sustain the move, suggesting it may be a gap or block-driven event rather than a news-driven continuation. The macro context (elevated 5-year inflation expectations) is not directly supportive of large-cap pharma like ABBV, which is not a typical beneficiary of inflation-reactive sectors. Without a clear fundamental driver, mean-reversion or consolidation into the close is at least as likely as continuation, warranting an uncertain stance.
?May 12, 1:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 3.64% with no identifiable catalyst in recent headlines, suggesting this may be a gap-driven move without fresh fundamental support to sustain momentum into the close. The macro context (elevated 5Y inflation expectations) does not specifically benefit healthcare/pharma names like ABBV. With 150 minutes remaining, there is time for the move to extend, but absent a clear news catalyst and given the tendency for large gap-up moves without catalysts to partially fade mid-session, continuation is uncertain.
?May 12, 1:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 4% intraday with no accompanying headlines or identifiable catalyst visible in the data, suggesting this may be a gap or spike move without clear fundamental support for continuation. The macro context (elevated 5-year inflation expectations) is not directly relevant to a healthcare/pharma name like ABBV. With 165 minutes remaining there is time for continuation, but absent a clear catalyst, mean-reversion or consolidation is equally plausible, keeping conviction low.
?May 12, 12:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.40% today with no accompanying news catalysts visible, suggesting this could be a gap or technical move without a clear fundamental driver sustaining it. The macro context (elevated 5-year inflation expectations) is more relevant to commodities and TIPS sectors than healthcare/pharma, providing no directional tailwind. With 180 minutes remaining there is time for movement, but absent a catalyst and with a sizable move already priced in, mean reversion risk is meaningful.
?May 12, 12:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has already moved 3.19% intraday with no identifiable headline catalyst, suggesting this may be a gap-and-fade or thin-volume spike rather than a news-driven momentum move. The macro context (elevated inflation expectations via T5YIE) is not particularly favorable or unfavorable for a large-cap pharma/biotech like ABBV. With 195 minutes remaining and no clear catalyst to sustain the move, mean reversion is a plausible outcome, making continuation uncertain.
?May 12, 12:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.93% with no accompanying headlines or identifiable catalyst, suggesting the move may be driven by broader market sentiment or a gap that has already largely played out. The macro context highlights elevated inflation expectations (T5YIE 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 210 minutes remaining there is time for the move to extend, but without a clear fundamental catalyst, mean reversion or consolidation is equally plausible.
?May 12, 12:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.27% with no identifiable news catalyst in the recent headlines, suggesting this may be a gap or early-session move without a clear fundamental driver to sustain momentum into the close. The macro context (elevated 5-year inflation expectations) is not directly relevant to ABBV as a pharmaceutical stock. With 225 minutes remaining, there is time for either continuation or mean reversion, but the absence of a catalyst makes high-conviction continuation unlikely.
?May 12, 11:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.86% with no identifiable catalyst from recent headlines, suggesting the move may be driven by broader market sentiment or sector rotation rather than a company-specific event. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly favorable for large-cap pharma/biotech names like ABBV. With 240 minutes remaining and no clear fundamental driver, there is meaningful risk of mean reversion or profit-taking into the close, making continuation uncertain.
?May 12, 11:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 3.43% today with no accompanying news headlines to explain the catalyst, suggesting the move may be driven by sector rotation, options activity, or a gap that lacks fundamental support. With 255 minutes remaining there is time for continuation, but without a clear identifiable catalyst the probability of sustained momentum is moderate at best. The macro context (elevated inflation expectations) is not directly favorable for large-cap pharma, and absent a news driver, mean reversion risk is meaningful after a move of this magnitude.
?May 12, 11:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV has moved up 2.85% with no identifiable headline catalyst visible in the recent news feed, suggesting this may be a gap-up or early momentum move without a clear fundamental driver sustaining it. The macro context references elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for large-cap pharma like ABBV. With 270 minutes remaining, there is ample time for either continuation or mean reversion, but the absence of a confirmed catalyst makes high-confidence continuation unlikely.
?May 12, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up ~2.49% with no identifiable news catalyst driving the move, making it difficult to assess whether this is a fundamental re-rating or a temporary liquidity-driven spike. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not a direct tailwind for healthcare/pharma names like ABBV. With 285 minutes remaining there is time for a continuation, but without a clear catalyst, the move is more likely to partially mean-revert or consolidate near current levels rather than extend meaningfully into the close.
?May 12, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ABBV is up 2.24% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting the move may be driven by broader market or sector flows rather than a company-specific development. The macro context flags elevated 5-year inflation expectations (T5YIE at 1.9σ above trend), which is more relevant to gold, energy, and TIPS sectors than large-cap pharma like ABBV. With 300 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear fundamental catalyst makes sustained continuation uncertain.

← Back to dashboard